Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market Size, Share Report 2032

• Chapter 1. Preface
  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1. Market Research Process
    • 1.3.2. Market Research Methodology
• Chapter 2. Executive Summary
  • 2.1. Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market, 2024 - 2032, (USD Billion)
  • 2.2. Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market: Snapshot
• Chapter 3. Global Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market - Industry Analysis
  • 3.1. Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Growing Demand for Novel Drug Delivery System with Lesser Side Effects and Greater Efficacy
    • 3.2.2. Increasing Cancer Prevalence
  • 3.3. Restraints
    • 3.3.1. High Cost of Therapy
  • 3.4. Opportunity
    • 3.4.1. Technological Advancements
  • 3.5. Porter's Five Forces Analysis
  • 3.6. Market Attractiveness Analysis
    • 3.6.1. Market attractiveness analysis by type segment
    • 3.6.2. Market attractiveness analysis by regional segment
• Chapter 4. Global Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market - Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global novel drug delivery systems (NDDS) in cancer therapy market: company market share analysis, 2024
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New type launches
    • 4.2.3. Agreements, partnerships, collaborations and joint ventures
    • 4.2.4. Research and development and regional expansion
• Chapter 5. Global Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market - Type Segment Analysis
  • 5.1. Global novel drug delivery systems (NDDS) in cancer therapy market overview: by type
    • 5.1.1. Global novel drug delivery systems (NDDS) in cancer therapy market revenue share, by type, 2024 and 2032
  • 5.2. Embolization Particles
    • 5.2.1. Global novel drug delivery systems (NDDS) in cancer therapy market by Embolization Particles, 2024-2032 (USD Billion)
  • 5.3. Nanoparticles
    • 5.3.1. Global novel drug delivery systems (NDDS) in cancer therapy market by Nanoparticles, 2024-2032 (USD Billion)
• Chapter 6. Global Novel Drug Delivery Systems (NDDS) in Cancer Therapy Market - Regional Analysis
  • 6.1. Global novel drug delivery systems (NDDS) in cancer therapy market overview: by region
    • 6.1.1. Global novel drug delivery systems (NDDS) in cancer therapy market revenue share, by region, 2024 and 2032
  • 6.2. North America
    • 6.2.1. North America novel drug delivery systems (NDDS) in cancer therapy market, by country, 2024-2032 (USD Billion)
    • 6.2.2. North America novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.2.3. The U.S.
      • 6.2.3.1. The U.S. novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.2.4. Rest of North America
      • 6.2.4.1. Rest of North America novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
  • 6.3. Europe
    • 6.3.1. Europe novel drug delivery systems (NDDS) in cancer therapy market, by country, 2024-2032 (USD Billion)
    • 6.3.2. Europe novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.3.3. U.K.
      • 6.3.3.1. U.K. novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.3.4. France
      • 6.3.4.1. France novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.3.5. Germany
      • 6.3.5.1. Germany novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.3.6. Rest of Europe
      • 6.3.6.1. Rest of Europe novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market, by country, 2024-2032 (USD Billion)
    • 6.4.2. Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.4.3. China
      • 6.4.3.1. China novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.4.4. Japan
      • 6.4.4.1. Japan novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.4.5. India
      • 6.4.5.1. India novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.4.6. Rest of Asia Pacific
      • 6.4.6.1. Rest of Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
  • 6.5. Latin America
    • 6.5.1. Latin America novel drug delivery systems (NDDS) in cancer therapy market, by country, 2024-2032 (USD Billion)
    • 6.5.2. Latin America novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.5.3. Brazil
      • 6.5.3.1. Brazil novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
    • 6.5.4. Rest of Latin America
      • 6.5.4.1. Rest of Latin America novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
  • 6.6. Middle East & Africa
    • 6.6.1. Middle East & Africa novel drug delivery systems (NDDS) in cancer therapy market, 2024-2032 (USD Billion)
    • 6.6.2. Middle East & Africa novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
• Chapter 7. Company Profiles
  • 7.1. Celgene Corporation
    • 7.1.1. Overview
    • 7.1.2. Financials
    • 7.1.3. Type Portfolio
    • 7.1.4. Business Strategy
    • 7.1.5. Recent Developments
  • 7.2. Shire
    • 7.2.1. Overview
    • 7.2.2. Financials
    • 7.2.3. Type Portfolio
    • 7.2.4. Business Strategy
    • 7.2.5. Recent Developments
  • 7.3. Samyang Biopharmaceuticals Corporation
    • 7.3.1. Overview
    • 7.3.2. Financials
    • 7.3.3. Type Portfolio
    • 7.3.4. Business Strategy
    • 7.3.5. Recent Developments
  • 7.4. Merrimack Pharmaceuticals, Inc.
    • 7.4.1. Overview
    • 7.4.2. Financials
    • 7.4.3. Type Portfolio
    • 7.4.4. Business Strategy
    • 7.4.5. Recent Developments
  • 7.5. GALEN
    • 7.5.1. Overview
    • 7.5.2. Financials
    • 7.5.3. Type Portfolio
    • 7.5.4. Business Strategy
    • 7.5.5. Recent Developments
  • 7.6. Johnson & Johnson Services, Inc.
    • 7.6.1. Overview
    • 7.6.2. Financials
    • 7.6.3. Type Portfolio
    • 7.6.4. Business Strategy
    • 7.6.5. Recent Developments
  • 7.7. Teva Pharmaceutical Industries Ltd.
    • 7.7.1. Overview
    • 7.7.2. Financials
    • 7.7.3. Type Portfolio
    • 7.7.4. Business Strategy
    • 7.7.5. Recent Developments
  • 7.8. BTG
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. Type Portfolio
    • 7.8.4. Business Strategy
    • 7.8.5. Recent Developments
  • 7.9. Spectrum Pharmaceuticals, Inc.
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Type Portfolio
    • 7.9.4. Business Strategy
    • 7.9.5. Recent Developments

Table Of Figures

List of Figures

1. Market research process
2. Market research methodology
3. Global novel drug delivery systems (NDDS) in cancer therapy market, 2024-2032 (USD Billion)
4. Porter’s five forces analysis: novel drug delivery systems (NDDS) in cancer therapy market
5. Global novel drug delivery systems (NDDS) in cancer therapy market attractiveness, by type
6. Global novel drug delivery systems (NDDS) in cancer therapy market revenue share, by type, 2024 and 2032
7. Global novel drug delivery systems (NDDS) in cancer therapy market by embolization particles, 2024-2032 (USD Billion)
8. Global novel drug delivery systems (NDDS) in cancer therapy market by nanoparticles, 2024-2032 (USD Billion)
9. Global novel drug delivery systems (NDDS) in cancer therapy market revenue share, by region, 2024 & 2032
10. North America novel drug delivery systems (NDDS) in cancer therapy market, 2024-2032 (USD Billion)
11. Europe novel drug delivery systems (NDDS) in cancer therapy market, 2024-2032 (USD Billion)
12. Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market, 2024-2032 (USD Billion)
13. Latin America novel drug delivery systems (NDDS) in cancer therapy market, 2024-2032 (USD Billion)
14. Middle East & Africa novel drug delivery systems (NDDS) in cancer therapy market, 2024-2032 (USD Billion)

Table Of Tables

List of Tables

1. Global novel drug delivery systems (NDDS) in cancer therapy market: snapshot
2. Drivers for novel drug delivery systems (NDDS) in cancer therapy market: impact analysis
3. Restraints for novel drug delivery systems (NDDS) in cancer therapy market: impact analysis
4. North America novel drug delivery systems (NDDS) in cancer therapy market revenue, by country, 2024-2032 (USD Billion)
5. North America novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
6. North America novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
7. North America novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
8. The U.S. novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
9. The U.S. novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
10. The U.S. novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
11. Rest of North America novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
12. Rest of North America novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
13. Rest of North America novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
14. Europe novel drug delivery systems (NDDS) in cancer therapy market revenue, by country, 2024-2032 (USD Billion)
15. Europe novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
16. Europe novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
17. Europe novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
18. U.K. novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
19. U.K. novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
20. U.K. novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
21. France novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
22. France novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
23. France novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
24. Germany novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
25. Germany novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
26. Germany novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
27. Rest of Europe novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
28. Rest of Europe novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
29. Rest of Europe novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
30. Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market revenue, by country, 2024-2032 (USD Billion)
31. Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
32. Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
33. Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
34. China novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
35. China novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
36. China novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
37. Japan novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
38. Japan novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
39. Japan novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
40. India novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
41. India novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
42. India novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
43. Rest of Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
44. Rest of Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
45. Rest of Asia Pacific novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
46. Latin America novel drug delivery systems (NDDS) in cancer therapy market revenue, by country, 2024-2032 (USD Billion)
47. Latin America novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
48. Latin America novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
49. Latin America novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
50. Brazil novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
51. Brazil novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
52. Brazil novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
53. Rest of Latin America novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
54. Rest of Latin America novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
55. Rest of Latin America novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)
56. Middle  East & Africa novel drug delivery systems (NDDS) in cancer therapy market revenue, by type, 2024-2032 (USD Billion)
57. Middle  East & Africa novel drug delivery systems (NDDS) in cancer therapy market revenue, by nanoparticles, 2024-2032 (USD Billion)
58. Middle  East & Africa novel drug delivery systems (NDDS) in cancer therapy market revenue, by embolization particles, 2024-2032 (USD Billion)